Flagship Pioneering has patented a method using therapeutic chondrisome compositions to enhance metabolic function in target cells or tissues. The method involves isolating chondrisomes from cultured cells and delivering them to human subjects to decrease cholesterol levels, triglycerides, and improve cardiac function. GlobalData’s report on Flagship Pioneering gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Flagship Pioneering, Cancer treatment biomarkers was a key innovation area identified from patents. Flagship Pioneering's grant share as of February 2024 was 11%. Grant share is based on the ratio of number of grants to total number of patents.
Method of enhancing metabolic function using chondrisome compositions
A recently granted patent (Publication Number: US11903974B2) discloses a method for enhancing the metabolic function of a target cell or tissue by delivering a pharmaceutical composition containing isolated chondrisomes derived from cultured cells. The method involves a series of steps including dissociating cells, separating subcellular compositions, and suspending the chondrisome-enriched fraction in a solution to prepare a chondrisome preparation. This composition is intended for in-vivo delivery in human subjects and has shown promising results in decreasing serum cholesterol levels and triglycerides, as well as increasing cardiac function.
The patent claims cover various aspects of the method, including the use of chondrisomes in injured states of target cells or tissues, the persistence of chondrisomes in the target area for at least 6 hours, and their impact on mitochondrial permeability transition pore formation and Akt levels. The method also addresses the internalization of chondrisomes into target tissues, the selection of target tissues or cells from different systems in the body, and the potential applications for subjects at risk for various disorders. Additionally, the patent discusses the use of genetically engineered chondrisomes, loaded with cargo agents, and the administration of the composition to enhance the function of the target cells or tissues without triggering an unwanted immune response. Overall, the patent highlights the innovative approach of utilizing chondrisomes to improve metabolic function and offers a potential therapeutic strategy for a range of medical conditions.
To know more about GlobalData’s detailed insights on Flagship Pioneering, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
